Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Fernando Ulloa‐Montoya(GlaxoSmithKline (Switzerland)), Vincent Brichard(GlaxoSmithKline (Belgium)), Olivier Gruselle(GlaxoSmithKline (Switzerland)), Benjamin Dizier(GlaxoSmithKline (Switzerland)), Stefan Suciu(St James's University Hospital), Bart Spiessens(University of Maryland, Baltimore), Johan Vansteenkiste(KU Leuven), Jamila Louahed(Centre Hospitalier Universitaire Brugmann), Frédéric Lehmann(Télécom Paris), Wim H.J. Kruit(Erasmus MC), Alexander M.M. Eggermont(University Medical Center Utrecht)
Cited by 476
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k